JP6485914B2 - フルテメタモルの製造方法 - Google Patents
フルテメタモルの製造方法 Download PDFInfo
- Publication number
- JP6485914B2 JP6485914B2 JP2015211413A JP2015211413A JP6485914B2 JP 6485914 B2 JP6485914 B2 JP 6485914B2 JP 2015211413 A JP2015211413 A JP 2015211413A JP 2015211413 A JP2015211413 A JP 2015211413A JP 6485914 B2 JP6485914 B2 JP 6485914B2
- Authority
- JP
- Japan
- Prior art keywords
- flutemetamol
- extraction cartridge
- phase extraction
- general formula
- compound represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VVECGOCJFKTUAX-UHFFFAOYSA-N 2-[3-fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=C(F)C(NC)=CC=C1C1=NC2=CC=C(O)C=C2S1 VVECGOCJFKTUAX-UHFFFAOYSA-N 0.000 title claims description 11
- 229940113298 flutemetamol Drugs 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 63
- 150000001875 compounds Chemical class 0.000 claims description 44
- VVECGOCJFKTUAX-HUYCHCPVSA-N flutemetamol ((18)F) Chemical compound C1=C([18F])C(NC)=CC=C1C1=NC2=CC=C(O)C=C2S1 VVECGOCJFKTUAX-HUYCHCPVSA-N 0.000 claims description 39
- 238000001044 reversed-phase solid-phase extraction Methods 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 125000006239 protecting group Chemical group 0.000 claims description 11
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 230000002285 radioactive effect Effects 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 8
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 125000001802 myricyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000000746 purification Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 18
- 239000002243 precursor Substances 0.000 description 17
- 238000010511 deprotection reaction Methods 0.000 description 16
- -1 methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, n-pentoxy Chemical group 0.000 description 13
- 238000000354 decomposition reaction Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000002372 labelling Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- XBHOUXSGHYZCNH-UHFFFAOYSA-N 2-phenyl-1,3-benzothiazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2S1 XBHOUXSGHYZCNH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- HKVLOZLUWWLDFP-UHFFFAOYSA-M hydron;tetrabutylazanium;carbonate Chemical compound OC([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC HKVLOZLUWWLDFP-UHFFFAOYSA-M 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- GBSCSVUQCOTDTH-UHFFFAOYSA-N B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C Chemical compound B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C.C(CCC)[N+]1=CC=C(C=C1)C GBSCSVUQCOTDTH-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000004693 imidazolium salts Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- XHXXWWGGXFUMAJ-UHFFFAOYSA-N methanethiol;sodium Chemical compound [Na].SC XHXXWWGGXFUMAJ-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910001419 rubidium ion Inorganic materials 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Ink Jet (AREA)
- Saccharide Compounds (AREA)
Description
(a)下記一般式(1)で表わされる化合物を放射性フッ化物と反応させて下記一般式(2)で表わされる化合物を得る工程と、
(b)前記一般式(1)で表わされる化合物と前記一般式(2)で表わされる化合物を含む前記工程(a)の反応混合物に強塩基を作用させる工程と、
(c)前記工程(b)の後、逆相固相抽出カートリッジを用いて前記一般式(2)で表わされる化合物を精製する工程と、
(d)保護基を除去して、[18F]フルテメタモルを得る工程と、
を含む、フルテメタモルの製造方法
が提供される。
18F化標識工程では、上記一般式(1)で表わされる化合物(以下、「標識前駆体化合物」ともいう。)を放射性フッ化物と反応させて下記一般式(2)で表わされる化合物(以下、「18F標識中間体化合物」ともいう。)を得る。
前駆体分解工程では、標識前駆体化合物と18F標識中間体化合物とを含む18F化標識工程の反応混合物に、強塩基を作用させる。これにより、18F化標識工程の反応混合物中に含まれる残渣の標識前駆体化合物が高極性化合物に変換される。これら高極性化合物としては、特許文献1の図1に示すものが考えられる。なお、前駆体分解工程では、18F標識中間体化合物は強塩基と反応せずに残存する。
第一の精製工程では、前駆体分解工程の後、逆相固相抽出カートリッジを用いて上記18F標識中間体化合物を精製する。これにより、18F標識中間体化合物と、前駆体分解工程で得られた高極性化合物とが分離される。
脱保護工程では、ヒドロキシ基及びアミノ基の保護基をそれぞれ除去して、[18F]フルテメタモルを得る。
第二の精製工程では、脱保護工程の後、逆相固相抽出カートリッジを用いて、[18F]フルテメタモルを精製する。
第三の精製工程では、第二の精製工程の後、親水性相互作用型(HILIC)固相抽出カートリッジを用いて[18F]フルテメタモルを精製する。
(a)18F化標識工程
[18O]水にサイクロトロンでプロトン照射して得られた[18F]フッ化物イオン含有[18O]水を、陰イオン交換カラムに通液し、[18F]フッ化物イオンを、吸着捕集した。次いで、該カラムを水(3mL)で洗浄した後、0.15mol/L炭酸水素テトラブチルアンモニウム水溶液(0.35mL)とアセトニトリル(1mL)を用いて溶出し、得られた溶出液を蒸散させて、ここに、6−エトキシメトキシ−2−(4’−(N−ホルミル−N−メチル)アミノ−3’−ニトロ)フェニルベンゾチアゾール(AH111907)(75μmol)のジメチルスルホキシド溶液(1mL)を加え、130℃で15分加熱した後、冷却した。
(b)前駆体分解工程
工程(a)の冷却後の反応液にナトリウムメトキシドのメタノール溶液(11%(w/w)、1mL)を加え、130℃で5分加熱し、冷却した。
(c)第一の精製工程
工程(b)の冷却後の反応液に水(2mL)を加え、トリアコンチルシリル化シリカゲル(C30)カラムに通液し、18F標識中間体化合物を保持させた。さらに、40%(v/v)アセトニトリル水溶液(6mL)を、反応容器を経由してC30カラムに通液して洗浄した後、再度40%(v/v)アセトニトリル水溶液(6mL)を直接C30カラムに通液して洗浄した。このC30カラムにエタノール(2mL)を通液して、溶出液を回収した。
(d)脱保護工程
工程(c)で回収した溶出液に4mol/L塩酸(2.0mL)を加え、125℃で5分加熱し、未精製の[18F]フルテメタモル溶液を得た。
(e)第二の精製工程
工程(d)で得られた未精製の[18F]フルテメタモル溶液を冷却後、水(10mL)を加え、工程(b)で使用したものとは異なる未使用のC30カラムに通液し、[18F]フルテメタモルをC30カラムに保持させた。このC30カラムに40%(v/v)アセトニトリル水溶液(6mL)を通液して洗浄した後、水(6mL)を通液して洗浄した。エタノール(3.5mL)でC30カラムから[18F]フルテメタモルを溶出した。
(f)第三の精製工程
工程(e)の溶出液を、アミノプロピル化シリカゲルを充填したカラム(NH2カラム)に通液した。工程(e)で使用したC30カラム、このNH2カラムの順に水(9.3mL)を通液して洗浄し、各溶出液を0.7%(w/v)ポリソルベート80及び1.2%(w/v)塩化ナトリウムを含む18.8mmol/Lリン酸緩衝液(37.2mL)を添加した容器に回収した。
実施例1〜3の工程(a)、(b)を実行し、以下の工程を実行した。
(c’)脱保護工程
得られた工程(b)の反応液に4mol/L塩酸(0.6mL)を加え、125℃で5分加熱し、未精製の[18F]フルテメタモル溶液を得た。
(d’)第一の精製工程
工程(c’)で得られた未精製の[18F]フルテメタモル溶液を冷却後、水(2mL)を加え、C30カラムに通液し、[18F]フルテメタモルを保持させた。さらに、40%(v/v)アセトニトリル水溶液(12mL)を、反応容器を経由してC30カラムに通液して洗浄した後、水(5mL)をC30カラムに通液して洗浄した。このC30カラムにアセトニトリル(2mL)を通液して、溶出液を回収した。
(e’)第二の精製工程
工程(d’)で得られた溶出液をNH2カラムに通液して精製後、さらにアセトニトリル(1mL)を通液し、これら溶液を混合した。
(f’)第三の精製工程
工程(e’)で得られた溶液に水(5mL)を加え、工程(d’)で使用したものとは異なる未使用のC30カラムに通液し、[18F]フルテメタモルをC30カラムに保持させた後、水(4mL)をC30カラムに3回通液して洗浄した。エタノール(3.5mL)をC30カラムに通液し、さらに水(9.3mL)をC30カラムに通液し、各溶出液を0.7%(w/v)ポリソルベート80及び1.2%(w/v)塩化ナトリウムを含む18.8mmol/Lリン酸緩衝液(37.2mL)を添加した容器に回収した。
なお、[18F]フルテメタモルの放射化学的純度は、及び、非放射性不純物の濃度は、以下に示す方法で分析した。
TLC法で行った。条件は、以下のとおり。
TLCプレート:Silica Gel 60 F254(メルク社製)
移動相:酢酸エチル/ジエチルアミン =100/1
測定機器:Rita Star(raytest社製)
UV検出器を備えたHPLC法にて行った。条件は、以下のとおり。
カラム:LunaC18(2)(Phenomenex社製、サイズ:4.6×150mm、3μm)
移動相:20mmoL酢酸アンモニウム緩衝液(pH6.0)/アセトニトリル=62/38→40/10(0→9分),40/10→10/90(9→10分),10/90(10→20分),10/90→62/38(20→20.5分),62/38(20.5→30分)
流速:1.0mL/分
検出器:紫外可視吸光光度計(検出波長:330nm)
Claims (8)
- (a)下記一般式(1)で表わされる化合物を放射性フッ化物と反応させて下記一般式(2)で表わされる化合物を得る工程と、
(b)前記一般式(1)で表わされる化合物と前記一般式(2)で表わされる化合物とを含む前記工程(a)の反応混合物に、強塩基を作用させる工程と、
(c)前記工程(b)の後、逆相固相抽出カートリッジを用いて前記一般式(2)で表わされる化合物を精製する工程と、
(d)保護基を除去して、[18F]フルテメタモルを得る工程と、
を含む、フルテメタモルの製造方法。
- 前記工程(c)は、
(c−1)前記一般式(2)で表わされる化合物を前記逆相固相抽出カートリッジに保持させる工程と、
(c−2)アセトニトリル、テトラヒドロフラン及び炭素数1〜3のアルキルアルコールからなる群から選択される1以上の有機溶剤と水との混液で、該逆相固相抽出カートリッジを洗浄する工程と、
(c−3)炭素数1〜3のアルキルアルコールで、該逆相固相抽出カートリッジから前記一般式(2)で表わされる化合物を溶出する工程と、
を含む、請求項1に記載のフルテメタモルの製造方法。 - 前記工程(c−2)において、アセトニトリルと水との混液で、該逆相固相抽出カートリッジを洗浄することを含む、請求項2に記載のフルテメタモルの製造方法。
- 前記工程(c−3)において、前記炭素数1〜3のアルキルアルコールがエタノールである、請求項2又は3に記載のフルテメタモルの製造方法。
- 前記工程(c)における逆相固相抽出カートリッジが、トリアコンチルシリル化シリカゲルを充填したものである、請求項1乃至4いずれか一項に記載のフルテメタモルの製造方法。
- (e)前記工程(d)の後、逆相固相抽出カートリッジを用いて[18F]フルテメタモルを精製する工程と、
(f)前記工程(e)の後、親水性相互作用型固相抽出カートリッジを用いて[18F]フルテメタモルを精製する工程と、
を更に含む、請求項1乃至5いずれか一項に記載のフルテメタモルの製造方法。 - 前記工程(e)における逆相固相抽出カートリッジが、トリアコンチルシリル化シリカゲルを充填したものである、請求項6に記載のフルテメタモルの製造方法。
- 前記工程(f)における親水性相互作用型固相抽出カートリッジが、アミノプロピル化シリカゲルを充填したものである、請求項6又は7に記載のフルテメタモルの製造方法。
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015211413A JP6485914B2 (ja) | 2015-10-28 | 2015-10-28 | フルテメタモルの製造方法 |
MX2018005046A MX2018005046A (es) | 2015-10-28 | 2016-10-17 | Metodo para producir flutemetamol. |
KR1020187011715A KR102668514B1 (ko) | 2015-10-28 | 2016-10-17 | 플루트메타몰의 제조 방법 |
EP16782221.2A EP3368518B1 (en) | 2015-10-28 | 2016-10-17 | Method for producing flutemetamol |
CA2998985A CA2998985C (en) | 2015-10-28 | 2016-10-17 | Method for producing flutemetamol |
PCT/EP2016/074840 WO2017071980A1 (en) | 2015-10-28 | 2016-10-17 | Method for producing flutemetamol |
AU2016344537A AU2016344537B2 (en) | 2015-10-28 | 2016-10-17 | Method for producing flutemetamol |
US15/764,309 US10472338B2 (en) | 2015-10-28 | 2016-10-17 | Method for producing [18F]flutemetamol |
BR112018007545-0A BR112018007545B1 (pt) | 2015-10-28 | 2016-10-17 | Método para produzir [18f] flutemetamol |
RU2018113741A RU2733398C2 (ru) | 2015-10-28 | 2016-10-17 | Способ получения флутеметамола |
ES16782221T ES2766474T3 (es) | 2015-10-28 | 2016-10-17 | Método para producir flutemetamol |
CN201680062917.1A CN108137520B (zh) | 2015-10-28 | 2016-10-17 | 用于生产氟美他酚的方法 |
IL258148A IL258148B (en) | 2015-10-28 | 2018-03-15 | Methods for producing flumetamol |
HK18108745.1A HK1249098A1 (zh) | 2015-10-28 | 2018-07-06 | 用於生產氟美他酚的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015211413A JP6485914B2 (ja) | 2015-10-28 | 2015-10-28 | フルテメタモルの製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017081847A JP2017081847A (ja) | 2017-05-18 |
JP6485914B2 true JP6485914B2 (ja) | 2019-03-20 |
Family
ID=57144967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015211413A Active JP6485914B2 (ja) | 2015-10-28 | 2015-10-28 | フルテメタモルの製造方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10472338B2 (ja) |
EP (1) | EP3368518B1 (ja) |
JP (1) | JP6485914B2 (ja) |
KR (1) | KR102668514B1 (ja) |
CN (1) | CN108137520B (ja) |
AU (1) | AU2016344537B2 (ja) |
CA (1) | CA2998985C (ja) |
ES (1) | ES2766474T3 (ja) |
HK (1) | HK1249098A1 (ja) |
IL (1) | IL258148B (ja) |
MX (1) | MX2018005046A (ja) |
RU (1) | RU2733398C2 (ja) |
WO (1) | WO2017071980A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6485914B2 (ja) | 2015-10-28 | 2019-03-20 | 日本メジフィジックス株式会社 | フルテメタモルの製造方法 |
JP6770837B2 (ja) * | 2016-06-28 | 2020-10-21 | 日本メジフィジックス株式会社 | 放射性フッ素標識有機化合物を製造する方法 |
EP3643710A4 (en) | 2017-06-23 | 2020-04-29 | Nihon Medi-Physics Co., Ltd. | PRODUCTION METHOD FOR RADIO-HALOGEN-MARKED COMPOUND AND PRODUCTION METHOD FOR RADIOPHARMACEUTICAL |
GB201805253D0 (en) * | 2018-03-29 | 2018-05-16 | Ge Healthcare Ltd Ip | Solid phase extraction |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1010280A3 (fr) * | 1996-05-02 | 1998-05-05 | Coincidence S A | Procede et dispositif de synthese de 2-[18f] fluoro-2-deoxy-d-glucose. |
GB0229686D0 (en) * | 2002-12-20 | 2003-01-29 | Amersham Plc | Solid-phase fluorination of benzothiazoles |
CA2438032C (en) * | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
WO2006133732A1 (en) * | 2005-06-17 | 2006-12-21 | Advanced Accelerator Applications | Process for synthesizing labelled compounds |
GB0516564D0 (en) | 2005-08-12 | 2005-09-21 | Ge Healthcare Ltd | Fluorination process |
NZ572936A (en) * | 2006-05-11 | 2011-01-28 | Nihon Mediphysics Co Ltd | Process for production of [18F]1-amino-3-fluorocyclobutanecarboxylic acid, [18F]FACBC |
AU2008292201B2 (en) * | 2007-08-30 | 2014-09-04 | Ge Healthcare Limited | Radiopharmaceutical composition |
WO2011044406A2 (en) * | 2009-10-08 | 2011-04-14 | Ge Healthcare Limited | Purification method |
JP6485914B2 (ja) | 2015-10-28 | 2019-03-20 | 日本メジフィジックス株式会社 | フルテメタモルの製造方法 |
-
2015
- 2015-10-28 JP JP2015211413A patent/JP6485914B2/ja active Active
-
2016
- 2016-10-17 US US15/764,309 patent/US10472338B2/en active Active
- 2016-10-17 MX MX2018005046A patent/MX2018005046A/es active IP Right Grant
- 2016-10-17 CN CN201680062917.1A patent/CN108137520B/zh active Active
- 2016-10-17 EP EP16782221.2A patent/EP3368518B1/en active Active
- 2016-10-17 CA CA2998985A patent/CA2998985C/en active Active
- 2016-10-17 WO PCT/EP2016/074840 patent/WO2017071980A1/en active Application Filing
- 2016-10-17 KR KR1020187011715A patent/KR102668514B1/ko active IP Right Grant
- 2016-10-17 AU AU2016344537A patent/AU2016344537B2/en active Active
- 2016-10-17 RU RU2018113741A patent/RU2733398C2/ru active
- 2016-10-17 ES ES16782221T patent/ES2766474T3/es active Active
-
2018
- 2018-03-15 IL IL258148A patent/IL258148B/en active IP Right Grant
- 2018-07-06 HK HK18108745.1A patent/HK1249098A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
IL258148A (en) | 2018-05-31 |
KR102668514B1 (ko) | 2024-05-24 |
CA2998985C (en) | 2023-10-31 |
RU2018113741A (ru) | 2019-11-28 |
IL258148B (en) | 2020-08-31 |
CA2998985A1 (en) | 2017-05-04 |
HK1249098A1 (zh) | 2018-10-26 |
US20190055207A1 (en) | 2019-02-21 |
US10472338B2 (en) | 2019-11-12 |
CN108137520A (zh) | 2018-06-08 |
MX2018005046A (es) | 2018-06-13 |
EP3368518B1 (en) | 2019-12-04 |
AU2016344537B2 (en) | 2020-09-17 |
ES2766474T3 (es) | 2020-06-12 |
AU2016344537A1 (en) | 2018-04-12 |
JP2017081847A (ja) | 2017-05-18 |
KR20180073581A (ko) | 2018-07-02 |
CN108137520B (zh) | 2022-06-21 |
BR112018007545A2 (pt) | 2018-10-23 |
EP3368518A1 (en) | 2018-09-05 |
RU2733398C2 (ru) | 2020-10-01 |
RU2018113741A3 (ja) | 2020-02-20 |
WO2017071980A1 (en) | 2017-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6485914B2 (ja) | フルテメタモルの製造方法 | |
JP6955347B2 (ja) | フルテメタモルの製造方法 | |
KR101605291B1 (ko) | 유기 플루오르화 지방족 화합물의 제조방법 및 정제방법 | |
JP6605034B2 (ja) | 有機フッ化化合物の製造方法及び精製方法 | |
US8076499B2 (en) | Method for preparing precursor of radioactive 3-iodobenzylguanidine | |
Okumura et al. | Method for producing [18 F] flutemetamol | |
JP4519774B2 (ja) | 放射性フッ素標識化合物の製造方法 | |
JP7159157B2 (ja) | 放射性フッ素標識化合物の製造方法および放射性医薬の製造方法 | |
BR112018007545B1 (pt) | Método para produzir [18f] flutemetamol | |
KR101592291B1 (ko) | 고순도 및 고비방사능의 [18f]플루오로-l-도파의 제조 방법 | |
JP2020093985A (ja) | 放射性フッ素標識2−(3−ピリジニル)−1h−ベンゾイミダゾール誘導体の製造方法および放射性薬剤の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20180521 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180521 |
|
TRDD | Decision of grant or rejection written | ||
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181220 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190122 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190215 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6485914 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |